Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchActive Not RecruitingNCT05041153
What this trial is testing

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Who this might be right for
Advanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage III Gastric Cancer AJCC v8+30 more
M.D. Anderson Cancer Center 15
Large-scale testing (Phase 3)Study completedNCT02625623
What this trial is testing

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Who this might be right for
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaGastric Cancer Third Line
EMD Serono Research & Development Institute, Inc. 371
Large-scale testing (Phase 3)Looking for participantsNCT06203600
What this trial is testing

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Who this might be right for
Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma+13 more
National Cancer Institute (NCI) 224
Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT07118527
What this trial is testing

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 600
Testing effectiveness (Phase 2)UnknownNCT04609176
What this trial is testing

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
Peking University 64
Early research (Phase 1)Not Yet RecruitingNCT07594548
What this trial is testing

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Who this might be right for
Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8+13 more
Northwestern University 18
Large-scale testing (Phase 3)Study completedNCT03802591
What this trial is testing

CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
CStone Pharmaceuticals 479
Testing effectiveness (Phase 2)Looking for participantsNCT07546812
What this trial is testing

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Who this might be right for
HER2-negativeGastroesophageal JunctionEsophageal Adenocarcinoma+1 more
Gilead Sciences 120
Large-scale testing (Phase 3)Active Not RecruitingNCT04704934
What this trial is testing

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Who this might be right for
Gastric Cancer, AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Daiichi Sankyo 490
Large-scale testing (Phase 3)Study completedNCT03675737
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC 1,579
Testing effectiveness (Phase 2)UnknownNCT05974059
What this trial is testing

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastric Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06730373
What this trial is testing

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Who this might be right for
HER2-positive Gastric CancerMetastatic Gastric CancerUnresectable Gastric Carcinoma
Qilu Hospital of Shandong University 110
Testing effectiveness (Phase 2)Study completedNCT00006081
What this trial is testing

Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer

Who this might be right for
Esophageal CancerGastric Cancer
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT02514551
What this trial is testing

Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 245
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)UnknownNCT04934618
What this trial is testing

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Nanfang Hospital, Southern Medical University 85
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06454435
What this trial is testing

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Who this might be right for
Gastric CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 158
Testing effectiveness (Phase 2)Looking for participantsNCT07102901
What this trial is testing

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Who this might be right for
Advanced Gastric CancerMetastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 351
Testing effectiveness (Phase 2)Ended earlyNCT04933227
What this trial is testing

Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Who this might be right for
Stomach NeoplasmsGastric CancerGastroesophageal Junction Adenocarcinoma
Hoffmann-La Roche 29
Next Page
377